Viruses and Type 1 Diabetes: Focus on the Enteroviruses

Pollution & threats to the environmen

Enhancing and neutralizing anti-coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes

Abstract Studies in prospective cohorts have suggested that enterovirus infections are associated with the appearance of islet autoantibodies that precede later appearance of type 1 diabetes (T1D). It was shown that in addition to an antibody-mediated anti-coxsackievirus (CV)-B neutralizing activity of serum from patients with T1D, there was also enhancing anti-CV-B activity in vitro. In this study the patterns of enhancing and neutralizing anti-CV activities were analyzed from consecutive serum samples collected from children who were followed from birth until they developed T1D in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study and compared to those in non-diabetic control children. The titers of serum neutralizing activity were analyzed against those CVs which were detected in the stools in these children (CV-B3, CV-B5 or CV-A4) using plaque assay. The enhancing activity of these serum samples was analysed by measuring interferon-alpha (INF-α) production in cultures of peripheral blood mononuclear cells (PBMC) inoculated with a mixture of these viruses and diluted serum. A sustained anti-CV enhancing activity was observed in consecutive serum samples in patients with T1D. The pattern of responses differed between children who developed T1D and control children. In patients, the anti-CV enhancing activity was predominant or even exclusive over the neutralizing activity, whereas in controls the enhancing and neutralizing activities were more balanced or the neutralizing activity was largely predominant. In conclusion, evaluating the anti-enterovirus neutralizing and enhancing activity of serum samples can be useful to investigate further the relationship between enteroviruses and the development of T1D. This article is protected by copyright. All rights reserved.Peer reviewe

Enhancing and neutralizing anti-coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes

Abstract Studies in prospective cohorts have suggested that enterovirus infections are associated with the appearance of islet autoantibodies that precede later appearance of type 1 diabetes (T1D). It was shown that in addition to an antibody-mediated anti-coxsackievirus (CV)-B neutralizing activity of serum from patients with T1D, there was also enhancing anti-CV-B activity in vitro. In this study the patterns of enhancing and neutralizing anti-CV activities were analyzed from consecutive serum samples collected from children who were followed from birth until they developed T1D in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study and compared to those in non-diabetic control children. The titers of serum neutralizing activity were analyzed against those CVs which were detected in the stools in these children (CV-B3, CV-B5 or CV-A4) using plaque assay. The enhancing activity of these serum samples was analysed by measuring interferon-alpha (INF-α) production in cultures of peripheral blood mononuclear cells (PBMC) inoculated with a mixture of these viruses and diluted serum. A sustained anti-CV enhancing activity was observed in consecutive serum samples in patients with T1D. The pattern of responses differed between children who developed T1D and control children. In patients, the anti-CV enhancing activity was predominant or even exclusive over the neutralizing activity, whereas in controls the enhancing and neutralizing activities were more balanced or the neutralizing activity was largely predominant. In conclusion, evaluating the anti-enterovirus neutralizing and enhancing activity of serum samples can be useful to investigate further the relationship between enteroviruses and the development of T1D. This article is protected by copyright. All rights reserved.Peer reviewe

Coxsackievirus B4 infection, inflammation and persistence

Les coxsackievirus du groupe B (CVB) sont des petits virus à ARN appartenant à au genre Enterovirus et à la famille des Picornaviridae. Chez, l’homme, les CVB sont responsables de nombreuses infections aiguës bénignes ou sévères. Ils sont également incriminés dans le développement de maladies chroniques telles que le diabète de type 1 (DT1). En effet, plusieurs données épidémio-cliniques sont en faveur d’un lien entre les entérovirus et notamment les CVB et le DT1. Deux mécanismes majeurs ont été proposés pour expliquer cette pathogenèse entérovirale du DT1. Il s’agit de l’activation « en passant » d’un environnement inflammatoire et la persistance virale qui concourent à l’initiation du processus auto-immun. Les études présentées dans cette thèse visent à comprendre les caractéristiques et conséquences de l’infection à CVB qui pourraient expliquer l’implication de ces mécanismes. Les résultats obtenus suggèrent que CVB4 (utilisé comme modèle des CVB) est un virus inflammatoire. In vitro, il induit la production de grandes quantités d’IFNα par les cellules mononuclées du sang (CMN). Néanmoins cette induction d’IFNα n’est possible qu’en cas de facilitation de l’infection par des anticorps non neutralisants, qui se traduit par une entrée importante du virus dans les cellules. Dans nos travaux, l’IFNα a été détecté dans le plasma de sujets diabétiques, et fréquemment associé à la présence d’ARN entéroviral. De même, parmi les CMN, les monocytes ont été identifiés comme les principales cellules cibles du virus. En dehors de l’IFNα, nous avons montré que CVB4 peut induire la synthèse de plusieurs autres cytokines pro-inflammatoires notamment l’IL-6 et le TNFα. De façon intéressante, l’infection des cellules n’est pas indispensable car cette induction est possible par des particules non infectieuses. Cette production de cytokines pro-inflammatoires par les CMN peut également être amplifiée par la facilitation de l’infection en présence de particules infectieuses de CVB4. Nous avons montré que les macrophages, cellules effectrices importantes de l’immunité innée au niveau tissulaire, peuvent produire en présence de CVB4 de l’IFNα et d’autres cytokines pro-inflammatoires. Les macrophages dérivés de CMN en présence de M-CSF (mais pas de GM-CSF) sont infectables par CVB4 et le virus peut persister dans ces cellules. CVB4 peut également établir une infection chronique productive de type « état porteur » dans des cellules canalaires pancréatiques. Les cellules chroniquement infectées peuvent être guéries grâce à un traitement par de la fluoxétine. Cette molécule utilisée dans le traitement de troubles psychiatriques, présente in vitro une activité antivirale vis-à-vis de certains entérovirus, et permet d’éliminer complètement en quelques semaines le virus des cellules chroniquement infectées par CVB4. Des modifications cellulaires ont été observées au niveau des cellules chroniquement infectées notamment une diminution de l’expression de PDX-1, une résistance à la lyse au cours d’une réinfection par CVB4, ainsi qu’une diminution très importante de l’expression du récepteur CAR. Ces modifications cellulaires acquises au cours de l’infection chronique pouvaient persister après l’élimination du virus. Les cellules chroniquement infectées présentent également un profil de microARNs très différent de celui des cellules non infectées. Une évolution du virus a été également observée avec des changements phénotypiques et génotypiques. L’ensemble de nos observations montre que les caractéristiques de l’infection à CVB4 sont compatibles avec les mécanismes évoqués dans la pathogenèse entérovirale du DT1 et renforcent l’hypothèse de l’implication des CVB dans cette maladie.Group B coxsackieviruses (CVB) are small RNA viruses belonging to Enterovirus genus and to the Picornaviridae family. In humans, CVB can cause numerous mild and severe acute infections. They are also thought to be involved in the development of chronic diseases such as type 1 diabetes (T1D). Several epidemiological and clinical data support a link between enteroviruses, especially CVB and T1D. Two main mechanisms have been described to explain this enteroviral pathogenesis of T1D including a “bystander activation” of an inflammatory environment and viral persistence. These mechanisms contribute to initiation of the autoimmune process. Our studies aimed to understand the features and outcomes of CVB infection that could explain their involvement in these mechanisms. The results suggest that CVB4 (used as CVB model) is an inflammatory virus. CVB4 induces in vitro the production by peripheral blood mononuclear cells (PBMCs) of high amounts of IFNα. However this induction is only possible when CVB4 infection is enhanced by non-neutralizing antibodies, resulting in increased viral entry in cells. We also reported detection of IFNα in plasma of T1D patients, commonly associated with enteroviral RNA. In addition, monocytes have been identified as major targets of enteroviruses among PBMCs. Besides IFNα, CVB4 can induce the synthesis of other proinflammatory cytokines, mainly IL-6 and TNFα. Interestingly, infection is not needed, since inactivated viral particles can induce these proinflammatory cytokines. In addition, the enhancing of CVB4 infection in PBMCs results in increased production of these cytokines. We have shown that macrophages that are known as major innate immunity effectors can produce IFNα and other proinflammatory cytokines upon infection with CVB4. Macrophages derived from PBMCs in presence of M-CSF (but not GM-CSF) can be infected by CVB4, and the virus can persist in these cells. CVB4 can also establish a productive, carrier-sate persistent infection in pancreatic ductal-like cells. The virus can be completely cleared from chronically-infected cells using fluoxetine. This molecule already used in the treatment of depression and other mental disorders, has displayed antiviral activity against many enteroviruses, and can completely clear CVB4 from chronically-infected cells within few weeks. Cellular changes have been observed during chronic infection including a reduced expression of PDX-1, a resistant profile to lysis upon superinfection with CVB4, and an important decrease of CAR expression. These changes can linger even after the clearance of CVB4. In addition the miRNA profile in chronically-infected ductal-like cells was clearly different from that of mock-infected cells. Some phenotypic and genotypic changes were also observed in the virus derived from chronic infection. Altogether, these findings show the features of CVB4 infection are compatible with mechanisms reported in the enteroviral pathogenesis of T1D, and support the hypothesis of involvement of CVB in this disease

Infection à coxsackievirus B4, inflammation et persistance

Group B coxsackieviruses (CVB) are small RNA viruses belonging to Enterovirus genus and to the Picornaviridae family. In humans, CVB can cause numerous mild and severe acute infections. They are also thought to be involved in the development of chronic diseases such as type 1 diabetes (T1D). Several epidemiological and clinical data support a link between enteroviruses, especially CVB and T1D. Two main mechanisms have been described to explain this enteroviral pathogenesis of T1D including a “bystander activation” of an inflammatory environment and viral persistence. These mechanisms contribute to initiation of the autoimmune process. Our studies aimed to understand the features and outcomes of CVB infection that could explain their involvement in these mechanisms. The results suggest that CVB4 (used as CVB model) is an inflammatory virus. CVB4 induces in vitro the production by peripheral blood mononuclear cells (PBMCs) of high amounts of IFNα. However this induction is only possible when CVB4 infection is enhanced by non-neutralizing antibodies, resulting in increased viral entry in cells. We also reported detection of IFNα in plasma of T1D patients, commonly associated with enteroviral RNA. In addition, monocytes have been identified as major targets of enteroviruses among PBMCs. Besides IFNα, CVB4 can induce the synthesis of other proinflammatory cytokines, mainly IL-6 and TNFα. Interestingly, infection is not needed, since inactivated viral particles can induce these proinflammatory cytokines. In addition, the enhancing of CVB4 infection in PBMCs results in increased production of these cytokines. We have shown that macrophages that are known as major innate immunity effectors can produce IFNα and other proinflammatory cytokines upon infection with CVB4. Macrophages derived from PBMCs in presence of M-CSF (but not GM-CSF) can be infected by CVB4, and the virus can persist in these cells. CVB4 can also establish a productive, carrier-sate persistent infection in pancreatic ductal-like cells. The virus can be completely cleared from chronically-infected cells using fluoxetine. This molecule already used in the treatment of depression and other mental disorders, has displayed antiviral activity against many enteroviruses, and can completely clear CVB4 from chronically-infected cells within few weeks. Cellular changes have been observed during chronic infection including a reduced expression of PDX-1, a resistant profile to lysis upon superinfection with CVB4, and an important decrease of CAR expression. These changes can linger even after the clearance of CVB4. In addition the miRNA profile in chronically-infected ductal-like cells was clearly different from that of mock-infected cells. Some phenotypic and genotypic changes were also observed in the virus derived from chronic infection. Altogether, these findings show the features of CVB4 infection are compatible with mechanisms reported in the enteroviral pathogenesis of T1D, and support the hypothesis of involvement of CVB in this disease.Les coxsackievirus du groupe B (CVB) sont des petits virus à ARN appartenant à au genre Enterovirus et à la famille des Picornaviridae. Chez, l’homme, les CVB sont responsables de nombreuses infections aiguës bénignes ou sévères. Ils sont également incriminés dans le développement de maladies chroniques telles que le diabète de type 1 (DT1). En effet, plusieurs données épidémio-cliniques sont en faveur d’un lien entre les entérovirus et notamment les CVB et le DT1. Deux mécanismes majeurs ont été proposés pour expliquer cette pathogenèse entérovirale du DT1. Il s’agit de l’activation « en passant » d’un environnement inflammatoire et la persistance virale qui concourent à l’initiation du processus auto-immun. Les études présentées dans cette thèse visent à comprendre les caractéristiques et conséquences de l’infection à CVB qui pourraient expliquer l’implication de ces mécanismes. Les résultats obtenus suggèrent que CVB4 (utilisé comme modèle des CVB) est un virus inflammatoire. In vitro, il induit la production de grandes quantités d’IFNα par les cellules mononuclées du sang (CMN). Néanmoins cette induction d’IFNα n’est possible qu’en cas de facilitation de l’infection par des anticorps non neutralisants, qui se traduit par une entrée importante du virus dans les cellules. Dans nos travaux, l’IFNα a été détecté dans le plasma de sujets diabétiques, et fréquemment associé à la présence d’ARN entéroviral. De même, parmi les CMN, les monocytes ont été identifiés comme les principales cellules cibles du virus. En dehors de l’IFNα, nous avons montré que CVB4 peut induire la synthèse de plusieurs autres cytokines pro-inflammatoires notamment l’IL-6 et le TNFα. De façon intéressante, l’infection des cellules n’est pas indispensable car cette induction est possible par des particules non infectieuses. Cette production de cytokines pro-inflammatoires par les CMN peut également être amplifiée par la facilitation de l’infection en présence de particules infectieuses de CVB4. Nous avons montré que les macrophages, cellules effectrices importantes de l’immunité innée au niveau tissulaire, peuvent produire en présence de CVB4 de l’IFNα et d’autres cytokines pro-inflammatoires. Les macrophages dérivés de CMN en présence de M-CSF (mais pas de GM-CSF) sont infectables par CVB4 et le virus peut persister dans ces cellules. CVB4 peut également établir une infection chronique productive de type « état porteur » dans des cellules canalaires pancréatiques. Les cellules chroniquement infectées peuvent être guéries grâce à un traitement par de la fluoxétine. Cette molécule utilisée dans le traitement de troubles psychiatriques, présente in vitro une activité antivirale vis-à-vis de certains entérovirus, et permet d’éliminer complètement en quelques semaines le virus des cellules chroniquement infectées par CVB4. Des modifications cellulaires ont été observées au niveau des cellules chroniquement infectées notamment une diminution de l’expression de PDX-1, une résistance à la lyse au cours d’une réinfection par CVB4, ainsi qu’une diminution très importante de l’expression du récepteur CAR. Ces modifications cellulaires acquises au cours de l’infection chronique pouvaient persister après l’élimination du virus. Les cellules chroniquement infectées présentent également un profil de microARNs très différent de celui des cellules non infectées. Une évolution du virus a été également observée avec des changements phénotypiques et génotypiques. L’ensemble de nos observations montre que les caractéristiques de l’infection à CVB4 sont compatibles avec les mécanismes évoqués dans la pathogenèse entérovirale du DT1 et renforcent l’hypothèse de l’implication des CVB dans cette maladie

Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4

This study reports the antiviral activity of the drug fluoxetine against some enteroviruses (EV). We had previously established a model of persistent coxsackievirus B4 (CVB4) infection in pancreatic cell cultures and demonstrated that fluoxetine could clear the virus from these cultures. We further report the emergence of resistant variants during the treatment with fluoxetine in this model. Four independent persistent CVB4 infections in Panc-1 cells were treated with fluoxetine. The resistance to fluoxetine was investigated in an acute infection model. The 2C region, the putative target of fluoxetine antiviral activity, was sequenced. However, Fluoxetine treatment failed to clear CVB4 in two persistent infections. The resistance to fluoxetine was later confirmed in HEp-2 cells. The decrease in viral titer was significantly lower when cells were inoculated with the virus obtained from persistently infected cultures treated with fluoxetine than those from susceptible mock-treated cultures (0.6 log TCID50/mL versus 4.2 log TCID50/mL, p < 0.0001). Some previously described mutations and additional ones within the 2C protein were found in the fluoxetine-resistant isolates. The model of persistent infection is an interesting tool for assessing the emergence of variants resistant to anti-EV molecules. The resistance of EV strains to fluoxetine and its mechanisms require further investigation

Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes

Beyond acute clinical conditions, the role of enteroviruses (EVs) in chronic human diseases has been described. Although they are considered as highly cytolytic viruses, EVs can persist in various tissues. The persistence is believed to play a major role in the pathogenesis of EV related chronic dis- eases such as type 1 diabetes (T1D). T1D is charac- terized by an autoimmune destruction of pancreatic beta cells, and results from interplay between a genetic predisposition, the immune system, and environmental factors. EVs and especially group B coxsackieviruses (CVB) have been the most incrimi- nated as exogenous agents involved in the develop- ment of T1D. Enteroviral persistence is the result of a virus-host coevolution combining a cell resistance to lysis through mutations or down-regulation of viral receptor, and a decrease of the viral replication by genomic modifications or the production of a sta- ble double-stranded RNA form. CVB can persist in pancreatic cells and therefore could trigger, in genet- ically predisposed individuals, the autoimmune destruction of beta cells mainly through an activa- tion of inflammation. The persistence of the virus in other tissues such as intestine, blood cells, and thy- mus has been described, and could also contribute to some extent to the enteroviral pathogenesis of T1D. The molecular and cellular mechanisms of CVB per- sistence and the link with the development of T1D should be investigated further

Coxsackievirus B4 Can Infect Human Peripheral Blood-Derived Macrophages

Beyond acute infections, group B coxsackieviruses (CVB) are also reported to play a role in the development of chronic diseases, like type 1 diabetes. The viral pathogenesis mainly relies on the interplay between the viruses and innate immune response in genetically-susceptible individuals. We investigated the interaction between CVB4 and macrophages considered as major players in immune response. Monocyte-derived macrophages (MDM) generated with either M-CSF or GM-CSF were inoculated with CVB4, and infection, inflammation, viral replication and persistence were assessed. M-CSF-induced MDM, but not GM-CSF-induced MDM, can be infected by CVB4. In addition, enhancing serum was not needed to infect MDM in contrast with parental monocytes. The expression of viral receptor (CAR) mRNA was similar in both M-CSF and GM-CSF MDM. CVB4 induced high levels of pro-inflammatory cytokines (IL-6 and TNFα) in both MDM populations. CVB4 effectively replicated and persisted in M-CSF MDM, but IFNα was produced in the early phase of infection only. Our results demonstrate that CVB4 can replicate and persist in MDM. Further investigations are required to determine whether the interaction between the virus and MDM plays a role in the pathogenesis of CVB-induced chronic diseases

Prospective Evaluation of a Commercial Dengue NS1 Antigen Rapid Diagnostic Test in New Caledonia

Dengue virus infection is endemic in New Caledonia, with outbreaks occurring every year. We evaluated the Biosynex® Dengue NS1 antigen rapid diagnostic test (RDT) for the early diagnosis of dengue in patients attending a local hospital in northern New Caledonia. Samples collected from patients suspected of dengue infection were tested with RDT at the local laboratory, and then sent to the reference laboratory for confirmation with real-time RT-PCR. A total of 472 samples were included during the study period. RT-PCR yielded a positive result in 154 samples (32.6%). The sensitivity and specificity of the NS1 antigen RDT were 79.9% and 96.2%, respectively. The performance of the RDT varied by the time of sampling and dengue virus serotype. In conclusion, Biosynex® Dengue NS1 antigen RDT showed a sensitivity and a specificity in the upper range usually reported for this type of test. Several factors can lead to a suboptimal sensitivity, and negative samples with suggestive clinical features should be retested with reference methods